epirubicin has been researched along with Radiation Pneumonitis in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (60.00) | 29.6817 |
| 2010's | 2 (40.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arriagada, R; Bourgier, C; Dunant, A; Heymann, S; Marsiglia, H; Mathieu, MC; Pessoa, EL; Spielmann, M; Uzan, C | 1 |
| Dong, XJ; Li, LY; Wang, MZ; Xia, Y; Zhang, L; Zhang, XT; Zhao, J; Zhong, W | 1 |
| De Giorgi, U; Emiliani, E; Frassineti, L; Giannini, M; Giovannini, N; Kopf, B; Marangolo, M; Palazzi, S; Rosti, G; Zumaglini, F | 1 |
| Bergh, J; Blomqvist, C; Hernberg, M; Keyriläinen, J; Maasilta, P; Virkkunen, P; Wiklund, T | 1 |
| Frangiadaki, C; Georgoulias, V; Giatromanolaki, A; Kakolyris, S; Koukourakis, MI; Kouroussis, C; Retalis, G; Sivridis, E | 1 |
2 trial(s) available for epirubicin and Radiation Pneumonitis
| Article | Year |
|---|---|
Feasibility of radiotherapy after high-dose dense chemotherapy with epirubicin, preceded by dexrazoxane, and paclitaxel for patients with high-risk Stage II-III breast cancer.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Combined Modality Therapy; Epirubicin; Feasibility Studies; Female; Filgrastim; Granulocyte Colony-Stimulating Factor; Heart Failure; Humans; Mastectomy, Segmental; Middle Aged; Neoplasm Staging; Paclitaxel; Prospective Studies; Radiation Pneumonitis; Radiodermatitis; Razoxane; Recombinant Proteins | 2006 |
Pulmonary toxicity after radiotherapy in primary breast cancer patients: results from a randomized chemotherapy study.
Topics: Adult; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cyclophosphamide; Drug Administration Schedule; Epirubicin; Female; Fluorouracil; Hematopoietic Stem Cell Transplantation; Humans; Middle Aged; Prospective Studies; Radiation Pneumonitis; Sensitivity and Specificity; Tomography, X-Ray Computed | 2002 |
3 other study(ies) available for epirubicin and Radiation Pneumonitis
| Article | Year |
|---|---|
Exclusive alternating chemotherapy and radiotherapy in nonmetastatic inflammatory breast cancer: 20 years of follow-up.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Brachial Plexus Neuropathies; Carcinoma, Ductal, Breast; Carcinoma, Lobular; Combined Modality Therapy; Cyclophosphamide; Dose Fractionation, Radiation; Doxorubicin; Drug Administration Schedule; Epirubicin; Female; Fibrosis; Fluorouracil; Follow-Up Studies; Heart; Humans; Inflammatory Breast Neoplasms; Methotrexate; Middle Aged; Neoplasm Recurrence, Local; Radiation Injuries; Radiation Pneumonitis; Survival Rate; Tamoxifen; Time Factors; Vincristine | 2012 |
[Therapeutic effects and prognostic factors for the limited-stage small cell lung cancer treated with multidisciplinary therapy].
Topics: Antineoplastic Combined Chemotherapy Protocols; Carboplatin; Chemoradiotherapy; Cisplatin; Combined Modality Therapy; Disease-Free Survival; Epirubicin; Esophagitis; Etoposide; Female; Humans; Lung Neoplasms; Male; Middle Aged; Myelopoiesis; Radiation Pneumonitis; Radiotherapy, Conformal; Remission Induction; Small Cell Lung Carcinoma; Survival Rate | 2012 |
Hypofractionated and accelerated radiotherapy with cytoprotection (HypoARC): a short, safe, and effective postoperative regimen for high-risk breast cancer patients.
Topics: Adult; Aged; Alkaline Phosphatase; Amifostine; Antineoplastic Combined Chemotherapy Protocols; Breast Neoplasms; Cohort Studies; Cyclophosphamide; Dose Fractionation, Radiation; Epirubicin; Female; Fluorouracil; Follow-Up Studies; Humans; Mastectomy; Mastectomy, Modified Radical; Middle Aged; Nausea; Radiation Pneumonitis; Radiation-Protective Agents; Radiobiology; Radiodermatitis; Radiotherapy, Adjuvant; Survival Analysis; Vomiting | 2002 |